Trans 038 Pharma (Amil) Flashcards
• Most common cause of dementia in the elderly.
Alzheimers Disease
• Manifest with an insidious loss of episodic memory followed
by slowly progressive dementia.
• Brain atrophy in the medial temporal lobes, spreading to
lateral and medial parietal, temporal lobes and lateral frontal
cortex
Alzheimer’s Disease
Histologic findings in AD?
• Histologically, lesions are neuritic plaques, containing beta
amyloid, neurofibrillary tangles.
Most important risk factor in Alzheimer’s Disease
• Most important risk factors: age >70 years and positive family
history
Major Genetic Risk in Alzheimer’s Disease
• Major genetic risk: e4 allele of ApoE gene
Forgetting of words, especially proper names, progressing to forgetting common nouns and until fluency of speech is impaired
Dysnomia
impaired facial recognition?
Prosopagnosia
Acetylcholinesterase inhibitors (3)
Donepezil
Rivastigmine
Galantamine
Target dose Donezepil?
10 mg daily
Target dose Rivastigmine?
6mg twice daily
Target dose Galantamine
24 mg daily, extended release
Acetylcholinesterase inhibitors MOA detailed?
- Patient with AD reduced cerebral content of choline acetyl transferase, which leads to a decrease in acetylcholine synthesis and impaired cortical cholinergic function
- Cholinesterase inhibitors (donepezil, rivastigmine and galantamine) increase cholinergic transmission by inhibiting cholinesterase at the synaptic cleft and provide modest symptomatic benefit in some patients with dementia
are considered symptomatic therapies and are not believed to be neuroprotective or to alter the underlying disease trajectory
AchE
When you give cholinesterase inhibitor there is increase cholinergic transmission. T or F?
T
- Oldest cholinesterase inhibitor still in use
* Remains a preferred and widely prescribed drug in this class due to its once-daily dosing and ease of use
Donepezil
Most common because it is the oldest cholinesterase inhibitor
Donepezil starting dose
Dose: Start at 5mg/day, increased to 10mg/day after 4-6 weeks
Unique AE of Donepezil?
Unique AEs: nightly dosing can be associated with vivid dreaming or nightmares
Other AEs: GI symptoms, symptomatic bradycardia, rhabdomyolysis, neuroleptic malignant syndrome
mental status changes. Madalas side effect ng anti-psychotic drugs. Potentially fatal.
what syndrome?
Neuroleptic malignant syndrome
• Available as a twice-daily tablet or solution and as a once-daily extended-release capsule (US)
When you use it in patients with only mild cognitive impairment there is increase mortality. Usually given to patients with moderate-severe cognitive impairment.
• Has been associated with increased mortality in patients with mild cognitive impairment
• Increase mortality has not been observed in patients treated for AD, mixed dementia or vascular dementia
Galantamine
Starting dose of Galantamine
• Starting dose: 8mg OD, increase to 16mg OD after 4 weeks then after 4 weeks maintain at target maintenance dose of 24mg OD after 4
what is the contraindication of Galantamine
DO NOT USE IN PATIENTS WITH END-STAGE RENAL DISEASE OR SEVERE HEPATIC IMPAIRMEN
• Available in oral and transdermal formulations
More famous is the transdermal, the patches. More tolerable and efficacy is similar.
• Transdermal patch is preferred over the oral formulation because of better tolerability and similar efficacy
Rivastigmine
Patches can cause skin irritation and application sites should be rotated. T or F?
T
NMDA Receptor Antagonist?
Memantine
Target dose memantine?
10 mg BID
is the principal excitatory amino acid neurotransmitter in cortical and hippocampal neurons
Glutamate
One of the receptors activated by glutamate is the ______ receptor, which is involved in learning and memory
NMDA
T or F? Excessive NMDA stimulation can be induced by ischemia and lead to excitotoxicity, suggesting that agents that block pathologic stimulation of NMDA receptors may protect against further damage in patients with vascular dementia
T
More appropriately used for vascular dementia.
NMDA receptor antagonists: Memantine
MC adverse effects of memantine
Dizziness
Other AE: confusion, hallucinations
Usual dose of memantine?
Usual dose: 5mg OD on the 1st week, 10mg OD on the 2nd week, 15mg/day on the 3rd week and 20mg OD on the 4th week onwards
Has been found
Chronic condition characterized clinically by episodes of focal disorders of the optic nerves, spinal cord and brain, which remit to a varying extent and recur over a period of many years and are usually progressive due to demyelination of nerves.
Multiple Sclerosis
Typical features include weakness, paraparesis, paresthesia, loss of sight, diplopia, nystagmus, dysarthria, tremor, ataxia, impairment of deep sensation and bladder dysfunction.
MS
Initial symptom of about half of the patients with MS?
• Weakness or numbness in one or more limbs is the initial symptom in about half of patients.
Diagnostic Criteria for MS?
2 or more typical attacks of CNS demyelination with objective evidence on examination for both lesions
2 clinical attacks c objective evidence on examination for only one lesion
one attack c objective evedence on examination of 2 or more lesions
one attack c objective evidence on examination for only one lesion (clinically isolated syndrome)
Progressive non relapting deficits suggesting of MS
MX of MS?
CORTICOSTEROIDS (E.G. METHYLPREDNISOLONE)
• Intravenous administration of massive doses of methylprednisolone (a bolus of 500 to 1000mg daily for 3-5 days) followed by high oral doses of prednisone (beginning with 60-80 mg daily and tapering to a lower dosage over a 12- to 20-day period) is generally effective in aborting or shortening an acute or subacute exacerbation of MS or of optic neuritis.
Adverse effects of corticosteroids in MS?
AEs: hypercortisolism, Cushing syndrome, hypertension, hyperglycemia and erratic diabetic control, osteoporosis, avascular necrosis of the head of the femur, cataracts, gastrointestinal hemorrhage and activation of tuberculosis or pneumocystis.
• Modestly alter the natural history of relapsing-remitting MS
Mas mahal ng kaunti
Delivered subcutaneously every 2 days
• Given subcutaneously every second day, long term
interferon Beta
Dose of Interferon beta for MS?
adverse effects?
- Dose: 30mcg or 6.6 million units
* AEs: development of antibodies to the drug; flu-like symptoms, malaise
- A.k.a COPOLYMER I
* Mimics actions of myelin basic protein (autoantigen)
glatiramer(glatiramer acetate)
Dose and Adverse effects of glatiramer
- Dose: 20mg daily via subcutaneous injection
* AEs: flushing, chest tightness, dyspnea, palpitations and severe anxiety
- Monoclonal antibody
- Alters various components of the immune response
- Directed against alpha-integrin in order to block lymphocyte and monocyte adhesion to endothelial cells and their migration through the vessel wall
- Used in rheumatoid arthritis and fistulizing Crohn disease
- Given monthly by IV route
Natalizumab
AEs: associated with the appearance of progressive multifocal leukoencephalopathy (PML)
which drug?/
Natalizumab
what are the agents that are used to control spasticity/
- Baclofen
- Tizanidine*
- Dantrolene
- Diazepam*
- Botulinum toxin
- Toxin derived from Clostridium botulinum
- Commonly found in canned foods. Most popular use is for its aesthetic indications (improvement of wrinkles, hyperhidrosis)
botolinum toxin